Actively Recruiting
68Ga-AAZTA-093 PET/CT: First-in-human Study
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-05-31
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.
CONDITIONS
Official Title
68Ga-AAZTA-093 PET/CT: First-in-human Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed prostate cancer patients, treated or untreated
- Completion of 68Ga-AAZTA-093 and 68Ga-PSMA-11 or 68Ga-PSMA-617 PET/CT scans within one week
- Signed written informed consent
You will not qualify if you...
- Known allergy to prostate specific membrane antigen (PSMA)
- Any medical condition that may interfere significantly with study participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Actively Recruiting
Research Team
W
Weibing Miao, MD
CONTACT
G
Guochang Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here